Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Is DBCG abreast of new developments?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Application of automated image analysis reduces the workload of manual screening of sentinel lymph node biopsies in breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jeanette Dupont Jensen
  • Anne-Vibeke Laenkholm
  • Ann Knoop
  • Marianne Ewertz Kvistgaard
  • Raj Bandaru
  • Weihua Liu
  • Wolfgang Hackl
  • J Carl Barrett
  • Humphrey Gardner
Vis graf over relationer
PIK3CA mutations are frequent in breast cancer and activate the PI3K/Akt pathway. Unexpectedly, PIK3CA mutation appears in general to be associated with better outcome. In a cohort of patients where both primary and metastatic lesions were available, the objective was to assess changes in PIK3CA mutations. We wished to discern whether selective pressures occur and the influence of PIK3CA mutation on time to recurrence.
OriginalsprogEngelsk
TidsskriftClinical Cancer Research
Vol/bind17
Udgave nummer4
Sider (fra-til)667-77
Antal sider11
ISSN1078-0432
DOI
StatusUdgivet - 15 feb. 2011

ID: 31067609